Barrick Mining Corporation Stock Price, News & Analysis

BioArctic AB's partner Eisai has completed a rolling Biologics License Application (BLA) submission to the FDA for Leqembi subcutaneous autoinjector for weekly maintenance dosing in early Alzheimer's disease treatment. The autoinjector would allow for 15-second home administration after completing the initial IV phase. The application is based on Clarity AD open-label extension study data. Leqembi is currently approved in multiple countries including the US, Japan, and China, with pending applications in 10 other regions. The FDA is also reviewing a separate application for monthly IV maintenance dosing with a PDUFA date of January 25, 2025.

BioArctic AB (NASDAQ Stockholm: BIOA B) partner Eisai presented three-year data for lecanemab (Leqembi®) at CTAD congress, showing increased benefits for early Alzheimer's patients. The drug demonstrated a 30% reduction in disease stage progression risk, with 46% of patients with low brain amyloid levels showing improved or maintained cognition after three years. The CDR-SB benefit expanded to -0.95 compared to ADNI-population at 36 months. Safety profile remained consistent, with most ARIA occurring in first six months. Data suggests continued treatment benefits even after plaque clearance, particularly in early-stage patients. In Great Britain's approved population, treatment showed 33% CDR-SB decline slowing versus 27% in total study population.

BioArctic AB's partner Eisai reported Leqembi® global revenue of JPY 10 billion for Q3 2024, marking a 60% increase from Q2 2024's JPY 6.3 billion. This resulted in a royalty payment of approximately SEK 70 million to BioArctic. Eisai leads Leqembi's development and regulatory submissions globally, with Biogen co-commercializing the product. BioArctic maintains commercialization rights in the Nordic region and is preparing for joint commercialization with Eisai pending European approval.

BioArctic AB announced that its co-founder, Professor Lars Lannfelt, received the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the CTAD congress in Madrid. The award recognizes his pioneering work in Alzheimer's disease research and drug development, particularly his contributions leading to lecanemab, a disease-modifying treatment for early Alzheimer's approved in multiple countries including the U.S., Japan, and China. Lannfelt founded BioArctic in 2003 with Pär Gellerfors to develop antibody treatments based on his discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab, developed in collaboration with Eisai, works by binding to and clearing specific forms of amyloid-beta from the brain.

Barnes Group Inc. (NYSE: B) reported third quarter 2024 financial results with sales of $388 million, up 7% year-over-year with organic growth of 4%. The company posted a net loss of $2.1 million, or -$0.04 per share, while adjusted EPS was $0.09. Notable highlights include strong Aerospace performance with a 49% increase in segment sales to $232 million and a significant OEM backlog of $1.80 billion. The company recently announced its pending acquisition by Apollo Funds for $47.50 per share in cash, valuing Barnes at approximately $3.6 billion enterprise value.

Hexagon AB announces plans to evaluate separating its Asset Lifecycle Intelligence (ALI) business through a Lex Asea distribution to shareholders. The new company ('NewCo') would include ETQ, Bricsys, and Utilities & Infrastructure businesses. NewCo, with approximately 5,000 employees, generated revenues of EUR 980 million with a 35% adjusted operating margin. The remaining Hexagon business has 19,600 employees with revenues of EUR 4,408 million and 28% adjusted operating margin. Mattias Stenberg, current ALI division President, would lead NewCo. The separation process is expected to take 12-18 months and requires board and shareholder approval.

BioArctic AB announced that its founder, Lars Lannfelt, will receive the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the CTAD Conference in Madrid from October 29 to November 1. The conference will feature presentations on lecanemab, including data on its clinical practice use and plasma biomarkers in the AHEAD 3-45 trial. Key sessions include three symposia focusing on lecanemab's continued treatment importance, real-world evidence from the U.S. and Japan, and combination therapy considerations. Two oral presentations will discuss lecanemab's treatment efficacy and AI-derived prognostic covariates, along with a poster presentation on transitioning from clinical trials to practice.

BioArctic AB's partner Eisai announced that Australia's Therapeutic Goods Administration (TGA) initially decided not to register lecanemab, an antibody for treating mild cognitive impairment and mild dementia due to Alzheimer's disease. Eisai plans to request reconsideration within 90 days, with TGA's final decision expected 60 days after. Lecanemab, developed through BioArctic and Eisai's collaboration, is already approved in several countries including the US, Japan, and China.

The antibody originated from BioArctic's research based on Professor Lars Lannfelt's work. Eisai leads global development and regulatory submissions, with Eisai and Biogen co-commercializing the product. BioArctic retains commercialization rights in the Nordic region and is preparing for joint commercialization with Eisai in Europe, pending approval.

Nearmap, a global leader in location intelligence solutions, has announced the expansion of its imagery coverage across the U.S. through a partnership with Hexagon's Content Program. This addition complements Nearmap's existing coverage of 87% of the U.S. population, allowing insurers to gain insights into less populated geographic regions.

The expanded coverage will be accessible through Partner Connect, the Betterview platform's ecosystem for integrating third-party geospatial datasets and tools. This enhancement enables insurance companies to:

• Optimize underwriting efficiency
• Reduce physical inspection spending
• Recommend risk mitigation steps to policyholders

Nearmap surveys over 100 million parcels in the United States up to three times per year, providing insurance companies with valuable location insights for better-informed decisions across the entire policy lifecycle.